Zobrazeno 1 - 4
of 4
pro vyhledávání: '"V L, Reichardt"'
Autor:
P, Brossart, A, Zobywalski, F, Grünebach, L, Behnke, G, Stuhler, V L, Reichardt, L, Kanz, W, Brugger
Publikováno v:
Cancer research. 60(16)
Interleukin (IL)-10 secretion by tumor cells was demonstrated to be one of the mechanisms by which tumor cells can escape immunological recognition and destruction. In dendritic cells (DCs), which are currently used for vaccination therapies for mali
Autor:
V L, Reichardt, C Y, Okada, A, Liso, C J, Benike, K E, Stockerl-Goldstein, E G, Engleman, K G, Blume, R, Levy
Publikováno v:
Blood. 93(7)
The idiotype (Id) determinant on the multiple myeloma (MM) protein can be regarded as a tumor-specific marker. Immunotherapy directed at the MM Id may stem the progression of this disease. We report here on the first 12 MM patients treated at our ins
Autor:
G D, Long, M D, Amylon, K E, Stockerl-Goldstein, R S, Negrin, N J, Chao, W W, Hu, A P, Nademanee, D S, Snyder, R T, Hoppe, N, Vora, R, Wong, J, Niland, V L, Reichardt, S J, Forman, K G, Blume
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 3(6)
Myeloablative therapy followed by allogeneic bone marrow transplantation (BMT) has proven to be curative therapy in patients with hematologic malignancies. Relapse, however, remains a major cause of treatment failure for patients with advanced diseas
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 3(3)
With conventional therapy, multiple myeloma (MM) has a poor prognosis. During the last few years, it has become clear that high-dose chemotherapy with autologous stem cell support can increase overall survival of MM patients, but further improvement